Dishman Carbogen Amc
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
March 18 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
DISHMAN CARBOGEN AMCIS LTD - APPROVES ISSUE OF UP TO 1 BILLION RUPEES NCDS ON PRIVATE PLACEMENT BASIS
Source text: ID:nBSEcbbKLF
Further company coverage: DSHM.NS
(([email protected];))
March 18 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
DISHMAN CARBOGEN AMCIS LTD - APPROVES ISSUE OF UP TO 1 BILLION RUPEES NCDS ON PRIVATE PLACEMENT BASIS
Source text: ID:nBSEcbbKLF
Further company coverage: DSHM.NS
(([email protected];))
** Shares of Dishman Carbogen Amcis DSHM.NS drop 10.5% to 205 rupees
** The pharmaceutical API manufacturing and drug development co posts third-quarter consol net loss of 129.7 million rupees ($1.4 mln) versus a profit of 46.3 million rupees year ago
** Third-quarter consol total income from operations up 5.5% Y/Y
** DSHM stock fell 8.5% in 2025
($1 = 90.5025 Indian rupees)
(Reporting by Vijay Malkar)
(([email protected];))
** Shares of Dishman Carbogen Amcis DSHM.NS drop 10.5% to 205 rupees
** The pharmaceutical API manufacturing and drug development co posts third-quarter consol net loss of 129.7 million rupees ($1.4 mln) versus a profit of 46.3 million rupees year ago
** Third-quarter consol total income from operations up 5.5% Y/Y
** DSHM stock fell 8.5% in 2025
($1 = 90.5025 Indian rupees)
(Reporting by Vijay Malkar)
(([email protected];))
Feb 3 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
DISHMAN CARBOGEN AMCIS DEC-QUARTER CONSOL NET LOSS AFTER TAX 129.7 MILLION RUPEES
DISHMAN CARBOGEN AMCIS DEC-QUARTER CONSOL TOTAL INCOME FROM OPERATIONS 7.20 BILLION RUPEES
Source text: [ID:]
Further company coverage: DSHM.NS
(([email protected];))
Feb 3 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
DISHMAN CARBOGEN AMCIS DEC-QUARTER CONSOL NET LOSS AFTER TAX 129.7 MILLION RUPEES
DISHMAN CARBOGEN AMCIS DEC-QUARTER CONSOL TOTAL INCOME FROM OPERATIONS 7.20 BILLION RUPEES
Source text: [ID:]
Further company coverage: DSHM.NS
(([email protected];))
Aug 26 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
DISHMAN CARBOGEN AMCIS LTD - COMPANY RECEIVES EIR FROM US FDA INDICATING INSPECTION CLOSURE
Source text: ID:nBSEbgtjyY
Further company coverage: DSHM.NS
(([email protected];;))
Aug 26 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
DISHMAN CARBOGEN AMCIS LTD - COMPANY RECEIVES EIR FROM US FDA INDICATING INSPECTION CLOSURE
Source text: ID:nBSEbgtjyY
Further company coverage: DSHM.NS
(([email protected];;))
April 21 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
SUBSIDIARY AWARDED DRUG MANUFACTURING LICENSE FROM CHINESE NMPA
Source text: ID:nBSEbg8Dhs
Further company coverage: DSHM.NS
(([email protected];;))
April 21 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
SUBSIDIARY AWARDED DRUG MANUFACTURING LICENSE FROM CHINESE NMPA
Source text: ID:nBSEbg8Dhs
Further company coverage: DSHM.NS
(([email protected];;))
April 9 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
UNIT RECEIVES DRUG MANUFACTURING LICENSE FROM NMPA FOR SHANGHAI SITE
Source text: ID:nBSE2rt290
Further company coverage: DSHM.NS
(([email protected];;))
April 9 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
UNIT RECEIVES DRUG MANUFACTURING LICENSE FROM NMPA FOR SHANGHAI SITE
Source text: ID:nBSE2rt290
Further company coverage: DSHM.NS
(([email protected];;))
March 19 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
CARBOGEN AMCIS SAS GETS GMP COMPLIANCE CERTIFICATE FOR SAINT-BEAUZIRE SITE
Source text: ID:nNSEbdqVGx
Further company coverage: DSHM.NS
(([email protected];))
March 19 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
CARBOGEN AMCIS SAS GETS GMP COMPLIANCE CERTIFICATE FOR SAINT-BEAUZIRE SITE
Source text: ID:nNSEbdqVGx
Further company coverage: DSHM.NS
(([email protected];))
** Shares of Dishman Carbogen Amcis DSHM.NS rise 2.6% to 211.4 rupees
** Contract research, manufacturing services provider approves issuance of NCDs worth up to 500 million rupees ($5.74 million) on private placement basis
** Stock trades above 100-day moving avg
** Stock down 23.7% so far this year, after a 58.2% climb in 2024
($1 = 87.0550 Indian rupees)
(Reporting by Aleef Jahan in Bengaluru)
** Shares of Dishman Carbogen Amcis DSHM.NS rise 2.6% to 211.4 rupees
** Contract research, manufacturing services provider approves issuance of NCDs worth up to 500 million rupees ($5.74 million) on private placement basis
** Stock trades above 100-day moving avg
** Stock down 23.7% so far this year, after a 58.2% climb in 2024
($1 = 87.0550 Indian rupees)
(Reporting by Aleef Jahan in Bengaluru)
March 12 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
DISHMAN CARBOGEN AMCIS LTD - BOARD APPROVES ISSUE OF DEBENTURES AGGREGATING UP TO 500 MILLION RUPEES
Source text: ID:nBSEbnPycq
Further company coverage: DSHM.NS
(([email protected];))
March 12 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
DISHMAN CARBOGEN AMCIS LTD - BOARD APPROVES ISSUE OF DEBENTURES AGGREGATING UP TO 500 MILLION RUPEES
Source text: ID:nBSEbnPycq
Further company coverage: DSHM.NS
(([email protected];))
March 7 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
TO CONSIDER AND APPROVE PROPOSAL OF FUND RAISING
Source text: ID:nBSE5ktT4X
Further company coverage: DSHM.NS
(([email protected];;))
March 7 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
TO CONSIDER AND APPROVE PROPOSAL OF FUND RAISING
Source text: ID:nBSE5ktT4X
Further company coverage: DSHM.NS
(([email protected];;))
Feb 12 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
DEC-QUARTER CONSOL NET PROFIT 46.3 MILLION RUPEES
DEC-QUARTER CONSOL TOTAL INCOME FROM OPERATIONS 6.82 BILLION RUPEES
Further company coverage: DSHM.NS
(([email protected];))
Feb 12 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
DEC-QUARTER CONSOL NET PROFIT 46.3 MILLION RUPEES
DEC-QUARTER CONSOL TOTAL INCOME FROM OPERATIONS 6.82 BILLION RUPEES
Further company coverage: DSHM.NS
(([email protected];))
Jan 10 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
DISHMAN CARBOGEN AMCIS - UNIT SUCCESSFULLY COMPLETES SWISSMEDIC INSPECTION OF VIONNAZ FACILITY
DISHMAN CARBOGEN AMCIS LTD - VIONNAZ SITE'S GMP CERTIFICATION SUCCESSFULLY RENEWED
Source text: ID:nBSE4rn4gx
Further company coverage: DSHM.NS
(([email protected];;))
Jan 10 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
DISHMAN CARBOGEN AMCIS - UNIT SUCCESSFULLY COMPLETES SWISSMEDIC INSPECTION OF VIONNAZ FACILITY
DISHMAN CARBOGEN AMCIS LTD - VIONNAZ SITE'S GMP CERTIFICATION SUCCESSFULLY RENEWED
Source text: ID:nBSE4rn4gx
Further company coverage: DSHM.NS
(([email protected];;))
** Shares of Dishman Carbogen Amcis DSHM.NS rise 16.2% to 208 rupees
** The pharma co posted Q2 consol net PAT of 330.9 mln rupees ($3.9 mln) vs loss of 409 mln rupees a year ago; rev from ops rose 35% Y/Y
** Co says earnings were helped by higher commercial sales and rollover of some shipments which got pushed to Q2 from Q1
** More than 6.1 mln shares change hands, 13.2X its 30-day avg
** Stock up 20% YTD
($1 = 84.4025 Indian rupees)
(Reporting by Ashna Teresa Britto in Bengaluru)
** Shares of Dishman Carbogen Amcis DSHM.NS rise 16.2% to 208 rupees
** The pharma co posted Q2 consol net PAT of 330.9 mln rupees ($3.9 mln) vs loss of 409 mln rupees a year ago; rev from ops rose 35% Y/Y
** Co says earnings were helped by higher commercial sales and rollover of some shipments which got pushed to Q2 from Q1
** More than 6.1 mln shares change hands, 13.2X its 30-day avg
** Stock up 20% YTD
($1 = 84.4025 Indian rupees)
(Reporting by Ashna Teresa Britto in Bengaluru)
** Shares of India's Dishman Carbogen Amcis DSHM.NS up 8.8% after rising as much as 9.2% earlier in the day
** U.S. Food and Drug Administration has completed inspections at unit's Swiss sites; conclusions classified as "no action indicated" - drugmaker
** Stock set for its third straight week of gains, if trends hold
** YTD, DSHM has gained 6.2%
(Reporting by Hritam Mukherjee in Bengaluru)
(([email protected];))
** Shares of India's Dishman Carbogen Amcis DSHM.NS up 8.8% after rising as much as 9.2% earlier in the day
** U.S. Food and Drug Administration has completed inspections at unit's Swiss sites; conclusions classified as "no action indicated" - drugmaker
** Stock set for its third straight week of gains, if trends hold
** YTD, DSHM has gained 6.2%
(Reporting by Hritam Mukherjee in Bengaluru)
(([email protected];))
June 27 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
UNIT COMPLETED US FDA INSPECTION OF MANUFACTURING SITES LOCATED IN HUNZENSCHWIL AND AARAU, IN SWITZERLAND
INSPECTIONS AT BOTH SITES WERE CONCLUDED WITH NO FORM 483 AND CLASSIFIED AS NO ACTION INDICATED
Source text for Eikon: ID:nNSE9qgPW2
Further company coverage: DSHM.NS
(([email protected];))
June 27 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
UNIT COMPLETED US FDA INSPECTION OF MANUFACTURING SITES LOCATED IN HUNZENSCHWIL AND AARAU, IN SWITZERLAND
INSPECTIONS AT BOTH SITES WERE CONCLUDED WITH NO FORM 483 AND CLASSIFIED AS NO ACTION INDICATED
Source text for Eikon: ID:nNSE9qgPW2
Further company coverage: DSHM.NS
(([email protected];))
March 18 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
UNIT SUCCESSFULLY COMPLETED ANVISA AUDIT OF ITS FACILITY IN SHANGHAI, CHINA
INSPECTION CONCLUDED WITH NO CRITICAL, NO MAJOR OBSERVATIONS RAISED
GOOD MANUFACTURING PRACTICE CERTIFICATE GRANTED TO SITE BY AUTHORITY
Source text for Eikon: ID:nBSE13kGCD
Further company coverage: DSHM.NS
(([email protected];))
March 18 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
UNIT SUCCESSFULLY COMPLETED ANVISA AUDIT OF ITS FACILITY IN SHANGHAI, CHINA
INSPECTION CONCLUDED WITH NO CRITICAL, NO MAJOR OBSERVATIONS RAISED
GOOD MANUFACTURING PRACTICE CERTIFICATE GRANTED TO SITE BY AUTHORITY
Source text for Eikon: ID:nBSE13kGCD
Further company coverage: DSHM.NS
(([email protected];))
March 8 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
US- FDA INSPECTION AT CO'S FACILITY IN BAVLA, AHMEDABAD SUCCESSFULLY COMPLETED
US FDA INSPECTION WAS CONCLUDED WITH FEW PROCEDURAL OBSERVATIONS
Source text for Eikon: ID:nBSE5089YT
Further company coverage: DSHM.NS
(([email protected];))
March 8 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
US- FDA INSPECTION AT CO'S FACILITY IN BAVLA, AHMEDABAD SUCCESSFULLY COMPLETED
US FDA INSPECTION WAS CONCLUDED WITH FEW PROCEDURAL OBSERVATIONS
Source text for Eikon: ID:nBSE5089YT
Further company coverage: DSHM.NS
(([email protected];))
Jan 23 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
BAVLA SITE HAS BEEN DECLARED GMP COMPLIANT BY JAPANESE PHARMACEUTICALS AND MEDICAL DEVICES AGENCY
Further company coverage: DSHM.NS
(([email protected];))
Jan 23 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
BAVLA SITE HAS BEEN DECLARED GMP COMPLIANT BY JAPANESE PHARMACEUTICALS AND MEDICAL DEVICES AGENCY
Further company coverage: DSHM.NS
(([email protected];))
Sept 21 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
BAVLA SITE WAS SUCCESSFULLY JOINTLY INSPECTED BY EDQM AND ITALIAN MEDICINES AGENCY
FINAL REPORT IS AWAITED
Source text for Eikon: ID:nBSE6pgbQp
Further company coverage: DSHM.NS
(([email protected];))
Sept 21 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
BAVLA SITE WAS SUCCESSFULLY JOINTLY INSPECTED BY EDQM AND ITALIAN MEDICINES AGENCY
FINAL REPORT IS AWAITED
Source text for Eikon: ID:nBSE6pgbQp
Further company coverage: DSHM.NS
(([email protected];))
Aug 9 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
JUNE-QUARTER CONSOL NET PAT 170 MILLION RUPEES VERSUS 40.1 MILLION RUPEES
JUNE-QUARTER CONSOL TOTAL INCOME 7.3 BILLION RUPEES VERSUS 5.46 BILLION RUPEES
Source text for Eikon: ID:nBSE4Cfy6t
Further company coverage: DSHM.NS
(([email protected];;))
Aug 9 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
JUNE-QUARTER CONSOL NET PAT 170 MILLION RUPEES VERSUS 40.1 MILLION RUPEES
JUNE-QUARTER CONSOL TOTAL INCOME 7.3 BILLION RUPEES VERSUS 5.46 BILLION RUPEES
Source text for Eikon: ID:nBSE4Cfy6t
Further company coverage: DSHM.NS
(([email protected];;))
** Shares of Dishman Carbogen Amcis Ltd DSHM.NS tumble as much as 12.16% to a near three-month low of 114.50 rupees
** Supplier of specialty chemicals and active pharmaceutical ingredients reports widened net loss after tax in March quarter to 707.2 mln rupees, compared to 446.2 mln rupees Y/Y
** Loss widened due to fall in lower core profit margin in Dutch business due to high raw material costs; higher power and fuel costs also weighed on earnings: DSHM
** Trading volume is 1.97 mln shares as of 11:17 a.m. IST, 2.4x the 30-day avg - Refinitiv data
($1 = 81.7800 Indian rupees)
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463;))
** Shares of Dishman Carbogen Amcis Ltd DSHM.NS tumble as much as 12.16% to a near three-month low of 114.50 rupees
** Supplier of specialty chemicals and active pharmaceutical ingredients reports widened net loss after tax in March quarter to 707.2 mln rupees, compared to 446.2 mln rupees Y/Y
** Loss widened due to fall in lower core profit margin in Dutch business due to high raw material costs; higher power and fuel costs also weighed on earnings: DSHM
** Trading volume is 1.97 mln shares as of 11:17 a.m. IST, 2.4x the 30-day avg - Refinitiv data
($1 = 81.7800 Indian rupees)
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463;))
May 23 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
INDIA'S DISHMAN CARBOGEN AMCIS LTD MARCH-QUARTER CONSOL NET LOSS AFTER TAX 707.2 MILLION RUPEES VERSUS LOSS 446.2 MILLION RUPEES
DISHMAN CARBOGEN AMCIS LTD MARCH-QUARTER CONSOL TOTAL INCOME FROM OPERATIONS 6.19 BILLION RUPEES VERSUS 5.69 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: DSHM.NS
(([email protected];))
May 23 (Reuters) - Dishman Carbogen Amcis Ltd DSHM.NS:
INDIA'S DISHMAN CARBOGEN AMCIS LTD MARCH-QUARTER CONSOL NET LOSS AFTER TAX 707.2 MILLION RUPEES VERSUS LOSS 446.2 MILLION RUPEES
DISHMAN CARBOGEN AMCIS LTD MARCH-QUARTER CONSOL TOTAL INCOME FROM OPERATIONS 6.19 BILLION RUPEES VERSUS 5.69 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: DSHM.NS
(([email protected];))
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Dishman Carbogen Amc do?
Dishman Carbogen Amcis Limited is a fully integrated CRAMS player with global presence offering end-to-end services in process research, development, and manufacturing of Active Pharmaceutical Ingredients.
Who are the competitors of Dishman Carbogen Amc?
Dishman Carbogen Amc major competitors are Zenotech Labs., Jeevan Scientific, Vivo Bio Tech, Sun Pharma Adv. Res, Syngene Internatl., Hikal, Suven Life Sciences. Market Cap of Dishman Carbogen Amc is ₹3,027 Crs. While the median market cap of its peers are ₹2,980 Crs.
Is Dishman Carbogen Amc financially stable compared to its competitors?
Dishman Carbogen Amc seems to be less financially stable compared to its competitors. Altman Z score of Dishman Carbogen Amc is 1.47 and is ranked 7 out of its 8 competitors.
Does Dishman Carbogen Amc pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Dishman Carbogen Amc latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Dishman Carbogen Amc allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Accounts Receivable
How strong is Dishman Carbogen Amc balance sheet?
Dishman Carbogen Amc balance sheet is weak and might have solvency issues
Is the profitablity of Dishman Carbogen Amc improving?
Yes, profit is increasing. The profit of Dishman Carbogen Amc is ₹97.45 Crs for TTM, ₹3.24 Crs for Mar 2025 and -₹153.45 Crs for Mar 2024.
Is the debt of Dishman Carbogen Amc increasing or decreasing?
Yes, The net debt of Dishman Carbogen Amc is increasing. Latest net debt of Dishman Carbogen Amc is ₹1,784 Crs as of Mar-26. This is greater than Mar-25 when it was ₹1,070 Crs.
Is Dishman Carbogen Amc stock expensive?
Dishman Carbogen Amc is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Dishman Carbogen Amc is 31.06, while 3 year average PE is 27.7. Also latest EV/EBITDA of Dishman Carbogen Amc is 8.51 while 3yr average is 12.72.
Has the share price of Dishman Carbogen Amc grown faster than its competition?
Dishman Carbogen Amc has given lower returns compared to its competitors. Dishman Carbogen Amc has grown at ~-4.99% over the last 8yrs while peers have grown at a median rate of 4.2%
Is the promoter bullish about Dishman Carbogen Amc?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Dishman Carbogen Amc is 59.32% and last quarter promoter holding is 59.32%.
Are mutual funds buying/selling Dishman Carbogen Amc?
The mutual fund holding of Dishman Carbogen Amc is decreasing. The current mutual fund holding in Dishman Carbogen Amc is 1.06% while previous quarter holding is 1.08%.